Brexit Pharmaceutical Trade Implications

In this webinar, Dr. Pete Gough, Vice President at NSF Pharmaceutical Services, EMEA looks at the implication of Brexit on trade between the UK and the EU and vice-versa.
The Brexit Pharmaceutical Trade Implications webinar looks at the following issues:
• Northern Ireland Protocol and how Centrally Authorised Marketing Authorisations remain valid and how Northern Ireland remains in the EMVO.
• Re-testing and QP Certification of product exported from the UK in to the EU.
• The implications of Brexit for UK exports into the EU.
• Multi-country packs.
• The impact of Brexit on GMP.
• Exclusions to the EU-UK trade deal.
• The post-Brexit role of the MHRA.
• The information needed to register a product with a centralized authorization in the EU to a GB/UK Marketing Authorisation.
• The process of applying for a Marketing Authorisation in the UK/GB.
• Batch release testing in the UK.
• The role of the QP (Qualified Person) and QP Certification.
• The new Responsible Person register being created by the MHRA.

Related Articles:
The NSF.org Knowledge Library has hundreds of articles on issues of interest to life science professionals. Here are a few related to the webinar above:

Whitepaper: Brexit Implications for UK Pharmaceutical Administration:
https://www.nsf.org/knowledge-library...

Whitepaper: Risk Management, Sterile Pharmaceutical Products and a Post-Brexit UK Pharma Industry:
https://www.nsf.org/knowledge-library...

NSF Pharma Biotech Consulting Services: Read more about our consulting services here.
https://www.nsf.org/consulting/health...

Read more in the Knowledge Library here:
https://www.nsf.org/knowledge-library...

#brexit #regulatoryaffairs